Primary immunoglobulin A nephropathy (IgAN) is a kidney disease that happens when an antibody, called IgA, builds up in the kidneys. This can make your kidneys swell and not work well. The kidneys ...
The price you pay for Tarpeyo may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...
STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has ...
More common side effects of Tarpeyo (budesonide) include swelling of your hands, legs, ankles, or feet, acne, headache, high blood pressure, and muscle spasms. Tarpeyo can cause side effects that ...
Two years after securing an accelerated approval for its primary immunoglobulin A nephropathy (IgAN) therapy Tarpeyo (budesonide), Calliditas Therapeutics has scored a full FDA endorsement for the ...
We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales ...
- TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, ...
Credit: Calliditas. The conversion to regular approval was based on data from an additional 165 patients with biopsy-proven IgAN in the phase 3 NeflgArd trial. The conversion to regular approval was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results